Compare Prudential PLC (PUK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs GeneDx Holdings Corp — how do they compare? Prudential PLC trades at $27.1 (market cap $34.05B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Prudential PLC is far larger — about 13.3× GeneDx Holdings Corp's market cap, and Prudential PLC pays a 2.03% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| PUK | WGS | |
|---|---|---|
Market Cap | $34.05B | $2.56B |
Sector | Financials | Technology |
52-Week High | $33.61 | $167.51 |
52-Week Low | $24.98 | $34.51 |
Enterprise Value | $33.60B | $2.60B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $27.42, down 1.19% with bearish technical signals but strong fundamentals including 14.52% net margin and 19.24% ROE. Recent earnings show mixed results with Q2 2026 missing expectations while maintaining revenue growth to $27.4B in 2025. The company demonstrates improved cash flow generation with $1.93B net cash flow in 2025 and continues shareholder returns through dividends.
The stock presents value with a 9.64 P/E ratio amid analyst optimism (50% buy ratings), though China regulatory risks and technical bearishness warrant caution. Long-term growth prospects in Asian markets and capital return initiatives support investment case, but investors should monitor execution of the five-year strategic reshaping plan.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
